Clinical Trial Update: Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating golidocitinib in combination with PD-1 inhibitors as maintenance therapy for previously untreated extensive-stage small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Golidocitinib (golidocitinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: SCLC, SCLC, Extensive Stage | Phase 2 | Status: RECRUITING